POU2F1 and colorectal carcinoma: Interestingly, our previous findings have shown that POU2F1 silencing specifically inhibits glycolysis and the PPP activity to suppress the ROS-mediated DNA damage and apoptosis, promoting the proliferation and oxaliplatin resistance in CRC cells 7, suggesting that POU2F1 may be a promising therapeutic target.